Anti-PD-1 antibodies have been at the forefront of this success but the first of the ICI to be introduced, anti-CTLA-4 antibodies, have faced difficulties preventing broad therapeutic application, despite evidence of an enduring anti-tumour immunity in some cancers, notably melanoma. Here, CTLA4 is linked to cancer.